REGENXBIO prices upsized IPO at $22, above the original range

REGENXBIO, which is developing gene therapies for rare diseases with a proprietary delivery platform, raised $139 million by offering 6.3 million shares at $22, above the originally proposed $17 to $19 range. REGENXBIO will list on the Nasdaq under the symbol RGNX. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray acted as joint bookrunners on the deal.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.